Breast Cancer Clinical Trials in Zhengzhou, Henan
16 recruitingZhengzhou, Henan, China
Showing 1–16 of 16 trials
Recruiting
Phase 1Phase 2
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Breast CancerOvarian CancerProstate Cancer+3 more
Acerand Therapeutics (Shanghai) Limited298 enrolled14 locationsNCT06380660
Recruiting
Phase 3
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
Breast Cancer
Risen (Suzhou) Pharma Tech Co., Ltd.312 enrolled2 locationsNCT07207070
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 1
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors
Breast CancerLocally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.26 enrolled7 locationsNCT05461768
Recruiting
Phase 3
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Breast Cancer
Laekna Limited256 enrolled55 locationsNCT04851613
Recruiting
Phase 1
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
Breast CancerPancreatic CancerGastric Cancer+6 more
GONGCHU Biotechnology Co., Ltd21 enrolled1 locationNCT06508307
Recruiting
Phase 1
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
Breast CancerOvarian CancerProstate Cancer+4 more
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd30 enrolled2 locationsNCT06666270
Recruiting
Phase 2
A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer
Breast Cancer
Henan Cancer Hospital60 enrolled2 locationsNCT05394285
Recruiting
Phase 3
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
Breast Cancer
Henan Cancer Hospital812 enrolled1 locationNCT07057427
Recruiting
Phase 3
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.642 enrolled25 locationsNCT07003074
Recruiting
Phase 2
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Breast CancerHER2-positive Breast Cancer
Henan Cancer Hospital610 enrolled1 locationNCT05918328
Recruiting
Phase 2
Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
Breast Cancer
Zhenzhen Liu369 enrolled1 locationNCT05475678
Recruiting
Not Applicable
Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction
Breast Cancer
Fudan University80 enrolled6 locationsNCT05512286
Recruiting
Phase 2
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.42 enrolled16 locationsNCT06452706
Recruiting
Phase 3
Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer
Breast Cancer
Henan Cancer Hospital1,979 enrolled1 locationNCT05063136
Recruiting
Phase 3
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Breast Cancer
Genor Biopharma Co., Ltd.350 enrolled52 locationsNCT05851014